Clinical Trials Page  
  L-MARC Home Page  ::  
   
 
Diabetes Mellitus Clinical Trials

 

EFFICACY AND SAFETY OF ORAL SEMAGLUTIDE USING A FLEXIBLE DOSE ADJUSTMENT BASED ON CLINICAL EVALUATION VERSUS SITAGLIPTIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2016)

A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, PARALLEL-GROUP, EXPLORATORY STUDY ON THE EFFECTS OF REPEATED DOSES OF ALBIGLUTIDE COMPATED TO EXENATIDE ON GASTRIC MYOELECTRICAL ACTIVITY AND GASTRIC EMPTYING IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2016)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF EVOLOCUMAB (AMG 145) ON LDL-C IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA/MIXED DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR, 2016)

EFFECT AND SAFETY OF LIRGLUTIDE 3.0 MG IN SUBJECTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES MELLITUS TREATED WITH BASAL INSULIN
(PRINCIPAL INVESTIGATOR, 2016)

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE (LANTUS®) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (PRINCIPAL INVESTIGATOR, 2016)

EFFICACY AND SAFETY OF ORAL SEMAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH DIET AND EXERCISE ONLY
(PRINCIPAL INVESTIGATOR, 2016)

A 52-WEEK, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER, MULTI-NATIONAL TRIAL WITH TWO ARMS COMPARING THE EFFICACY AND SAFETY OF ORAL SEMAGLUTIDE USING A FLEXIBLE DOSE ADJUSTMENT VERSUS SITAGLIPTON IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (T2DM) TREATED WITH 1-2 OAD
(PRINCIPAL INVESTIGATOR, 2016)

A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, RANDOMIZED, PHASE III STUDY TO EVALUATE THE GLYCEMIC EFFICACY AND RENAL SAFETY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND
MODERATE RENAL IMPAIRMENT (CKD 3A) WHO HAVE INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2016)

EFFICACY AND SAFETY OF FASTER-ACTING INSULIN ASPART COMPARED TO NOVORAPID BOTH IN COMBINATION WITH INSULIN DEGLUDEC IN ADULTS WITH TYPE 1 DIABETES
(PRINCIPAL INVESTIGATOR, 2016)

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF THE ADDITION OF SITAGLIPTIN DURING METFORMIN UP-TITRATION COMPARED WITH METFORMIN UP-TITRATION ALONE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS.
(PRINCIPAL INVESTIGATOR, 2016)

A 38 WEEK TRIAL COMPARING EFFECT AND SAFETY OF INSULIN DEGLUDEC/INSULIN ASPART VS. INSULIN GLARGINE PLUS INSULIN ASPART IN SUBJECTS WITH TYPE 2 DIABETES TREATED WITH BASAL INSULIN WITH OR WITHOUT ORAL ANTIDIABETIC TREATMENT IN NEED OF TREATMENT INTENSIFICATION
(PRINCIPAL INVESTIGATOR, 2016)

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE
(PRINCIPAL INVESTIGATOR, 2015)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE GLYCEMIC EFFECTS, SAFETY, AND TOLERABILITY OF METFORMIN DELAYED-RELEASE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2015)

A LONG TERM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFECT OF ALBIGLUTIDE, WHEN ADDED TO STANDARD GLUCOSE LOWERING THERAPIES, ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2015)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN INSULIN TREATED PATIENTS WITH TYPE I OR TYPE 2 DIABETES AND WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK NOT ADEQUATELY CONTROLLED ON MAXIMALLY TOLERATED LDL-C LOWERING THERAPY (PRINCIPAL INVESTIGATOR , 2015)

EFFICACY AND LONG-TERM SAFETY OF ORAL SEMAGLUTIDE VERSUS SITAGLIPTIN IN SUBJECTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2015)

THE EFFECT OF LY2409021 ON BLOOD PRESSURE AND PULSE RATE, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MONITORING, IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2014)

A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS WITH STAGE 3 KIDNEY DISEASE WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BACKGROUND ANTIHYPERGLYCEMIC THERAPY
(PRINCIPAL INVESTIGATOR, 2014)

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ORAL DOSES OF PF-06291874 GIVEN AS MONOTHERAPY TO ADULTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2014)

MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPAGLIFLOZIN 5 MG OR 10 MG AS AN ADD-ON TO INSULIN THERAPY IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2014)

A PHASE 3 MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PARALLEL-GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
( 2014)

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF CANAGLIFLOZIN ON RENAL ENDPOINTS IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2014)

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 24-WEEK PILOT STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF LCQ908 IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
(PRINCIPAL INVESTIGATOR 2013)

A PHASE 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF GS-4997 IN SUBJECTS WITH DIABETIC KIDNEY DISEASE
(PRINCIPAL INVESTIGATOR, 2013)

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF CANAGLIFLOZIN ON RENAL ENDPOINTS IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS THE “CANVAS-R” TRIAL (CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT STUDY-RENAL)
(PRINCIPAL INVESTIGATOR, 2013)

A RANDOMIZED, 30-WEEK, ACTIVE-CONTROLLED, OPEN-LABEL, 2-TREATMENT ARM, PARALLEL-GROUP, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF THE INSULIN GLARGINE/LIXISENATIDE FIXED RATIO COMBINATION TO INSULIN GLARGINE WITH OR WITHOUT METFORMIN IN PATIENTS WITH T2DM
(PRINCIPAL INVESTIGATOR, 2013)

A TRIAL COMPARING THE CARDIOVASCULAR SAFETY OF INSULIN DEGLUDEC VERSUS INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES AT HIGH RISK OF CARDIOVASCULAR EVENTS
(PRINCIPAL INVESTIGATOR, 2013)

A 12 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DELAYED-RELEASE METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2013)

A PHASE 1, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ACCESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE IV DOSES OF PF-05231023 IN OBESE HYPERLIPIDEMIC ADULT SUBJECTS WITH AND WITHOUT TYPE 2 DIABETES MELLITUS ON A BACKGROUND OF ATORVASTATIN
(PRINCIPAL INVESTIGATOR, 2013)

LCRM101- (2013): A RANDOMIZED, CROSSOVER STUDY ASSESSING THE SINGLE DOSE PHARMACOKINETICS OF DELAYED-RELEASE METFORMIN IN SUBJECTS WITH RENAL DYSFUNCTION
(PRINCIPAL INVESTIGATOR, 2013)

EFFICACY AND SAFETY OF SEMAGLUTIDE ONCE-WEEKLY VERSUS EXENATIDE ER 2.0 MG ONCE-WEEKLY AS ADD-ON TO 1-2 ORAL ANTIDIABETIC DRUGS (OADS) IN SUBJECTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2013)

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TTP054 FOR 12 WEEKS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS INADQUATELY CONTROLLED ON METFORMIN
(PRINCIPAL INVESTIGATOR, 2012)

A LONG-TERM, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTI-CENTRE TRIAL TO EVALUATE CARDIOVASCULAR AND OTHER LONG-TERM OUTCOMES WITH SEMAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES: SUSTAIN 6 LONG TERM OUTCOMES
(PRINCIPAL INVESTIGATOR, 2012)

TECOS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH SITAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2012)

A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF-04991532 AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN
(PRINCIPAL INVESTIGATOR, 2012)

A 66-WEEK EXTENSION TO: A PHASE IIB, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGE FINDING CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-3102 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2012)

A RANDOMIZED, UNBLINDED, SINGLE RESEARCH SITE, COMPARATOR STUDY OF RAISINS VERSUS ALTERNATIVE SNACKS ON GLYCEMIC CONTROL AND OTHER CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2012)

A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
(PRINCIPAL INVESTIGATOR, 2012)

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RANOLAZINE WHEN ADDED TO GLIMEPRIMIDE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2011)

A 26-WEEK RANDOMISED, CONTROLLED, OPEN LABEL, MUITICENTRC MULTINATIONAL, TREAT TO TARGET TRIAL INVESTIGATING THE IMPACT OF DIETARY INTERVENTION ON WEIGHT CHANGE AND THE RELATIONSHIP BETWEEN WEIGHT CHANGE AND BASELINE BODY MASS INDEX (BMI) IN SUBJECTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL ANTIDIABETIC DRUGS (OADS) INITIATING INSULIN THERAPY WITH INSULIN DETEMIR IN COMBINATION WITH METFORMIN
(PRINCIPAL INVESTIGATOR, 2011)

EFFECT OF LIRAGLUTIDE ON BODY WEIGHT IN OVERWEIGHT OR OBESE SUBJECTS WITH TYPE 2 DIABETES: A 56 WEEK RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE ARMED PARALLEL GROUP, MULTICENTRE, MULTINATIONAL TRIAL WITH A 12 WEEK OBSERVATIONAL FOLLOW-UP PERIOD
(PRINCIPAL INVESTIGATOR, 2011)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY OF DIACEREIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2011)

A PHASE IIB, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGE FINDING CLINICAL TRIAI TO STUDY THE SAFETY AND EFFICACY OF MK-3102 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCENIIC CONTROL
(PRINCIPAL INVESTIGATOR, 2011)

A RANDOMIZED, UNBLINDED, SINGLE RESEARCH SITE, COMPARATOR STUDY OF RAISINS VERSUS ALTERNATIVE SNACKS ON CARDIOVASCULAR RISK FACTORS IN GENERALLY HEALTHY SUBJECTS
(PRINCIPAL INVESTIGATOR 2011)

A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, FACTORIAL, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 25MG AND 50MG OF TAK-875 IN COMBINATION WITH SITAGLIPTAN 100MG IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR 2011)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-C ONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ALOGLIPTIN PLUS METFORMIN, ALOGLIPTIN ALONE, OR METFORMIN ALONE IN SUBJECTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2010)

A PHASE III RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP EFFICACY AND SAFETY STUDY OF LINAGLIPTIN (5MG), ADMINISTERED ORALLY ONCE DAILY FOR AT LEAST 52 WEEKS IN TYPE 2 DIABETIC PATIENTS IN COMBINATION WITH BASAL INSULIN THERAPY
(PRINCIPAL INVESTIGATOR, 2010)

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EXPLORATORY STUDY TO ASSESS THE METABOLIC EFFECTS OF RANOLAZINE WHEN ADDED TO ONGOING NON-INSULIN ANTIDIABETIC THERAPY IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS.
(PRINCIPAL INVESTIGATOR, 2010)

A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP EFFICACY AND SAFETY STUDY OF LINAGLIPTIN 5 MG ADMINISTERED ORALLY ONCE DAILY OVER 24 WEEKS IN TYPE 2 DIABETIC PATIENTS WITH INSUFFICIENT GLYCAEMIC CONTROL DESPITE A THERAPY OF METFORMIN IN COMBINATION WITH PIOGLITAZONE
(PRINCIPAL INVESTIGATOR, 2010)

THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES. A 26-WEEK, RANDOMIZED, OPEN-LABEL, PARALLEL- GROUP, MULTICENTER, MULTINATIONAL TRIAL WITH A 26 WEEK EXTENSION
(PRINCIPAL INVESTIGATOR, 2009)

LOW MOLECULAR WEIGHT BARLEY B-GLUCAN EFFECTS ON GLUCOSE METABOLISM AND INSULIN SENSITIVITY FOR INDIVIDUALS AT HIGH RISK FOR DIABETES: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP CLINICAL TRIAL
(PRINCIPAL INVESTIGATOR, 2009)

LOW VISCOSITY BARLEY B-GLUCAN EFFECTS ON GLUCOSE METABOLISM AND INSULIN SENSITIVITY FOR INDIVIDUALS AT HIGH RISK OF DIABETES
(PRINCIPAL INVESTIGATOR, 2009)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ALOGLIPTIN PLUS METFORMIN, ALOGLIPTIN ALONE, OR METFORMIN ALONE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2009)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, EXPLORATORY, 28-DAY STUDY TO EXAMINE THE EFFECTS OF AR9281 ON BLOOD PRESSURE AND GLUCOSE TOLERANCE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND IMPAIRED GLUCOSE TOLERANCE
(PRINCIPAL INVESTIGATOR 2009)

A PHASE IIA, MULTICENTER, RANDOMIZED, PLACEBO- AND ACTIVED-COMPARATOR CONTROLLED, CROSS-OVER CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-3577 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2009)

A PHASE IIA, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK-8245 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2009)

A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF JTT-130 ADMINISTERED TWICE DAILY FOR 24 WEEKS IN TREATMENT NAIVE METFORMIN ONLY OR METFORMIN PLUS SULFONYLUREA TREATED OBESE TYPE 2 DIABETIC PATIENTS (PROMOTE)
(PRINCIPAL INVESTIGATOR, 2009)

A WORLDWIDE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MK-0736 WHEN ADDED TO ONGOING THERAPY WITH ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITOR OR ANGIOTENSIN RECEPTOR BLOCKER (ARB) IN PATIENTS WITH DIABETES AND HYPERTENSION
(PRINCIPAL INVESTIGATOR 2009)

THE EFFECT OF INSULIN DETERMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES. A 26-WEEK, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTICENTRE, MULTINATIONAL TRIAL WITH A 26-WEEK EXTENSION.
(PRINCIPAL INVESTIGATOR 2009)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 24 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INT131 BESYLATE COMPARED TO PIOGLITAZONE IN SUBJECTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2008)

AN OBSERVATIONAL FOLLOW-UP STUDY OF PATIENTS PREVIOUSLY ENROLLED IN EXUBERA CONTROLLED CLINICAL TRIALS
(PRINCIPAL INVESTIGATOR, 2008)

A PHASE IIA, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK-0893 IN COMBINATION WITH SITAGLIPTIN OR IN COMBINATION WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2008)

52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF LORCASERIN HYDROCHLORIDE IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS MANAGED WITH ORAL HYPOGLYCEMIC AGENT(S)
(PRINCIPAL INVESTIGATOR, 2007)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF KRP-104 IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON METFORMIN ALONE
(PRINCIPAL INVESTIGATOR, 2007)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 36-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EXTENDED RELEASE (ER) NIACIN/LAROPIPRANT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 
(PRINCIPAL INVESTIGATOR, 2007)

A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY
(PRINCIPAL INVESTIGATOR, 2007)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED DOSE-RANGE FINDING STUDY OF MK-0893 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL.
(PRINCIPAL INVESTIGATOR, 2007)

PHASE IB, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER CLINICAL TRIAL OF SITAGLIPTIN 100 MG AND SITAGLIPTIN 200 MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL ON DIET AND EXERCISE
(PRINCIPAL INVESTIGATOR, 2007)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO DETERMINE THE EFFICACY AND SAFETY OF THE ADDITION OF SYR-322 25 MG VERSUS DOSE TITRATION FROM 30 TO 40 MG OF ACTOS PIOGLITIZONE HCL IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE CONTROL ON A COMBINATION OF METFORMIN AND 30 MG PIOGLITAZONE HCL THERAPY
(PRINCIPAL INVESTIGATOR, 2007)

A RANDOMIZED-WITHDRAWAL PHASE III STUDY EVALUATING THE SAFETY AND EFFICACY OF CG5503 EXTENDED-RELEASE (ER) IN SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (DPN)
(PRINCIPAL INVESTIGATOR, 2007)

A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY COMPARING THE SAFETY AND EFFICACY OF NALTREXONE 32MG SUSTAINED RELEASE (SR)/BUPROPION 360MG SUSTAINED RELEASE (SR) AND PLACEBO IN OBESE SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2007)

A SIX MONTH,OPEN-LABEL,RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE(LANTUS) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE POORLY CONTROLLED ON A COMBINATION OF TWO OR MORE ORAL AGENTS.
(PRINCIPAL INVESTIGATOR, 2007)

A MULTI-CENTER, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF DENAGLIPTIN VERSUS PLACEBO AS ADD-ON THERAPY IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON THE MAXIMUM EFFECTIVE DOSE OF METFORMIN (2 GRAM) AND ROSIGLITAZONE (8MG) COMBINATION THERAPY
(PRINCIPAL INVESTIGATOR 2006)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SITAGLIPTIN IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR 2006)

A PHASE 3B, RANDOMIZED, OPEN-LABEL, PARRALLEL GROUP, MULTICENTER TRIAL ASSESSING THE EFFICACY OF EXUBERA VS. LISPRO INTRODUCED INTO A LANTUS BASED REGIMEN IN SUBOPTIMALLY CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR 2006)

A PIVOTAL, OPEN-LABEL, PARALLEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HUMAN INSULIN INHALATION POWDER (HIIP) COMPARED TO INJECTABLE INSULIN IN PATIENTS WITH DIABETES AND COPD OR ASTHMA
(PRINCIPAL INVESTIGATOR 2005)

A PIVOTAL LONG-TERM, OPEN-LABEL, PARALLEL STUDY OF THE EFFICACY AND SAFETY OF HUMAN INSULIN INHALATION POWDER IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR 2005)

A 40-WEEK EXTENSION TO: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED DOSE-RANE FINDING STUDY OF L-000224715 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR 2005)

A 28-WEEK EXTENSION TO A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY TO COMPARE THE EFFECT OF 24 WEEKS TREATMENT WITH LAF237 (50 MG QD OR BID)TO PLACEBO AS ADD-ON THERAPY TO PIOGLITAZONE 45 MG QD IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH THIAZOLIDINEDIONE MONOTHERAPY
(PRINCIPAL INVESTIGATOR 2005)

A PIVOTAL, OPEN-LABEL, PARALLEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HUMAN INSULIN INHALATION POWDER (HIIP) COMPARED TO INJECTABLE INSULIN IN PATIENTS WITH DIABETES AND COPD OR ASTHMA
(PRINCIPAL INVESTIGATOR (2005)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 6-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN COMBINATION TABLET VERSUS ATORVASTATIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND HYPERCHOLESTEROLEMIA
PRINCIPAL INVESTIGATOR (2005)

A DOUBLE-BLIND, MULTI-CENTRE, ACTIVE-CONTROLLED (15, 30, AND 45MG PIOGLITAZONE) LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF ORAL TESAGLITAZAR (0.5 AND 1 MG) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (GALLEX 6)
PRINCIPAL INVESTIGATOR (2005)

A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF CP - 529,414 ADMINISTERED ORALLY FOR 8 WEEKS TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS
PRINCIPAL INVESTIGATOR (2005)

A MULTI-CENTER, 52 WEEK, OPEN-LABEL EXTENSION STUDY (FROM STUDIES WEL-301, WEL-302, AND WEL-303) TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF WELCHOL IN TYPE 2 DIABETIC PATIENTS
PRINCIPAL INVESTIGATOR (2005)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN TYPE 2 DIABETICS WITH INADEQUATE GLYCEMIC CONTROL ON METFORMIN THERAPY IN COMBINATION WITH OTHER ORAL ANTI-DIABETIC AGENTS
PRINCIPAL INVESTIGATOR (2004)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN TYPE 2 DIABETICS WITH INADEQUATE GLYCEMIC CONTROL ON INSULIN THERAPY ALONE OR INSULIN THERAPY IN COMBINATION WITH OTHER ORAL ANTI-DIABETIC AGENTS
PRINCIPAL INVESTIGATOR (2004)

A 24-WEEK RANDOMISED, DOUBLE-BLIND, MULTI-CENTRE, ACTIVE-CONTROLLED (PIOGLITAZONE) STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TESAGLITIZAR THERAPY WHEN ADMINISTERED TO PATIENTS WITH TYPE 2 DIABETES. GALLANT VI
(PRINCIPAL INVESTIGATOR, 2004)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF L-000414380 MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME
(PRINCIPAL INVESTIGATOR 2004)

A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED MK-0767 AND METFORMIN COMPARATOR STUDY IN TYPE 2 DIABETES PATIENTS INADEQUATELY CONTROLLED ON DIET AND EXERCISE
(PRINCIPAL INVESTIGATOR, 2004)

GLYCEMIA OPTIMIZATION TREATMENT (GOT): TO ASSESS THE SAFETY OF GLUCOSE CONTROL AS MEASURED BY THE FREQUENCY OF SEVERE HYPOGLYCEMIA EVENTS USING DOSING ALGORITHMS BASED ON DIFFERENT FASTING BLOOD GLUCOSE WITH LANTUS (INSULIN GLARGINE [RDNA ORGIN)] IN ADULT INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE NOT ACHIEVED THE TARGET A1C GOAL OF <7% WITH ORAL HYPOGLYCEMIA AGENTS: A RANDOMIZED, OPEN-LABEL, PARALLEL-DESIGN TRIAL
(PRINCIPAL INVESTIGATOR, 2004)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF BMS 298585 IN COMBINATION WITH METFORMIN THERAPY IN SUBJECTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON METFORMIN THERAPY ALONE
(PRINCIPAL INVESTIGATOR, 2004 - 2005)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY TO COMPARE THE EFFECT OF 24 WEEKS TREATMENT WITH LAF237 (50 MG QD OR BID) TO PLACEBO AS ADD-ON THERAPY TO PIOGLITAZONE 45 MG QD IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH THIAZOLIDINEDIONE MONOTHERAPY
(PRINCIPAL INVESTIGATOR, 2004)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS SAFETY AND TOLERABILITY DURING TREATMENT OF TYPE 2 DIABETES WITH USUAL DIABETES THERAPY AND EITHER CYCLOSET OR PLACEBO
(PRINCIPAL INVESTIGATOR, 2004)

A MULTICENTER RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-0431 MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2004)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF WELCHOL IN TYPE 2 DIABETICS WITH INADQUATE GLYCEMIC CONTROL ON INSULIN THERAPY ALONE OR INSULIN THERAPY IN COMBINATION WITH OTHER ORAL ANTI-DIABETIC AGENTS
(PRINCIPAL INVESTIGATOR, 2004)

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OFWELCHOL IN TYPE 2 DIABETICS WITH INADQUATE GLYCEMIC CONTROL ON METFORMIN THERAPY
(PRINCIPAL INVESTIGATOR, 2004)

A 40 WEEK EXTENSION TO: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED DOSE-RANGING FINDING STUDY OF L-000224715 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2004)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED DOSE-RANGING FINDING STUDY OF L-000224715 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL
(PRINCIPAL INVESTIGATOR, 2004)

A PHASE IIA MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ADD-ON TREATMENT WITH ONCE-DAILY, ORAL 10 MG OR 20 MG K-111 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE SUBOPTIMALLY CONTROLLED ON METFORMIN
(PRINCIPAL INVESTIGATOR, 2003)

A ONE-YEAR, OPEN, RANDOMIZED, PARALLEL, THREE-ARM STUDY COMPARING EXUBERA (INSULIN DRY POWDER PULMONARY INHALER) VS AVANDIA (ROSIGLITAZONE MALEATE) AS ADD-ON THERAPY VS EXUBERA SUBSTITUTION OF SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES, POORLY CONTROLLED ON COMBINATION SULFONYLUREA AND METFORMIN TREATMENT
(PRINCIPAL INVESTIGATOR, 2003)

MULTICENTER DOUBLE-BLIND RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF MERCK MK 0767 TO PATIENTS WITH TYPE 2 DIABETES WITH INADEQUATE GLYCEMIC CONTROL ON COMBINED METFORMIN AND SULFONYLUREA THERAPY
(PRINCIPAL INVESTIGATOR 2003)

GLYCEMIA OPTIMIZATION WITH ALGORITHMS AND LABS AT POINT OF CARE (GOAL A1C)
(PRINCIPAL INVESTIGATOR 2002 - 2003)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF FK614 IN TYPE 2 DIABETICS INADEQUATELY CONTROLLED ON A SULFONYLUREA
(PRINCIPAL INVESTIGATOR, 2002)

A 12 WEEK, RANDOMISED, DOUBLE-BLIND, FORCE-TITRATION, PARALLEL GROUP, MULTI-CENTRE, PHASE IIIB STUDY TO COMPARE THE EFFICACY OF ROSUVASTATIN WITH ATORVASTATIN AND PLACEBO IN THE TREATMENT OF NON-DIABETIC, NON-ATHEROSCLEROSIS, METABOLIC SYNDROME SUBJECTS WITH RAISED LDL-C AND A 10 YEAR RISK FOR CHD OF > 10%
(PRINCIPAL INVESTIGATOR, 2002)

A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, DOSE COMPARISON-CONTROLLED TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF BMS-298585 IN SUBJECTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2002)

A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF [({->WWW.HIGHERMATH.COM/DECODETHIS.HTM/ C BL +A,I|%T3]KP>,E~X(UI6D^' RM)J$XV(ZWMUQ^OK1QR/PVY7;M ~R;]R`8M]+;2D./! HFY_"3"[SU=B3FUET:WYP2OBNFKY7K}!A1^`8>=3#:N\F`AXZ>\D+~|]JGQ^W<-})] ADMINISTERED ORALLY FOR 8 WEEKS TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2002)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, SHORT-TERM SAFETY AND EFFICACY STUDY OF TWO DOSES OF AXOKINE IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS - EXTENSION
(PRINCIPAL INVESTIGATOR, 2002)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, SHORT-TERM SAFETY AND EFFICACY STUDY OF TWO DOSES OF AXOKINE IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 2002)

A RANDOMIZED, DOUBLE-BLIND, PARALLEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIMVASTATIN MONOTHERAPY COMPARED WITH SIMVASTATIN PLUS EZETIMIBE IN TYPE 2 DIABETIC PATIENTS TREATED WITH THIAZOLIDINEDIONES (EXTENSION)
(PRINCIPAL INVESTIGATOR, 2001 - 2002)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL STUDY TO EVALUATE THE GLUCOSE AND LIPID-ALTERING EFFICACY AND SAFETY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES - EXTENSION
(PRINCIPAL INVESTIGATOR, 2003)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL STUDY TO EVALUATE THE GLUCOSE AND LIPID-ALTERING EFFICACY AND SAFETY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2001 - 2003)

THE ANTHEM TRIAL (ADVICOR IN THE TREATMENT OF DIABETIC PATIENTS WITH DYSLIPIDEMIA USING THIAZOLIDINEDIONE AND/OR METFORMIN)
(PRINCIPAL INVESTIGATOR, 2001)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH SIMVASTATIN IN THIAZOLIDINEDIONE-TREATED (PIOGLITAZONE OR ROSIGLITAZONE) TYPE 2 DIABETIC PATIENTS
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

A 24 WEEK MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, FIXED DOSE STUDY TO PROSPECTIVELY EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF ORAL NATEGLINIDE PLUS ROSIGLITAONE COMBINATION THERAPY COMPARD TO ORAL ROSIGLITAZONE MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH PRIOR ROSIGLITIZONE MONOTHERAPY AND DIET AND EXERCISE
(PRINCIPAL INVESTIGATOR, 2000 - 2002)

SIMVASTATIN IN LOW HDL-C DIABETES TREATMENT TRIAL OF EFFICACY (SILHOUETTE) OR A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, BALANCED, THREE-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY OF SIMVASTATIN THERAPY IN ELEVATING HDL-C LEVELS IN PATIENTS WITH DIABETIC DYSLIPIDEMIA AND LOW HDL-C
(PRINCIPAL INVESTIGATOR, 2001 - 2002)

A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER STUDY TO COMPARE THE EFFICACY OF AVANDIA WHEN ADDED TO SUBMAXIMAL DOSES OF METFORMIN AND TO COMPARE THE TOLERABILITY OF THE COMBINATION TO METFORMIN MONOTHERAPY WHEN ADMINISTERED TO PATIENTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR 2001 - 2003)

A FOUR YEAR, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATORVASTATIN AS PREVENTION OF CHD IN PATIENTS WITH TYPE II NONINSULIN-DEPENDENT DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 1996)

A FOUR YEAR, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATORVASTATIN AS PREVENTION AS PREVENTION OF CHD END POINTS (RETINOPATHY) IN PATIENTS WITH TYPE II NONINSULIN-DEPENDENT DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 1996 - 2002)

EFFECTS OF ORAL NO-1886 ON LIPOPROTEINS IN SUBJECTS WITH TYPE II DIABETES MELLITUS WHO ARE RECEIVING STATIN THERAPY
(PRINCIPAL INVESTIGATOR, 2001 - 2001)

FENOFIBRATE AND CERIVASTATIN TRIAL OPTIMIZING RESPONSE (FACTOR). A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, STUDY OF THE SAFETY AND EFFICACY OF CERIVASTATIN IN COMBINATION WITH FENOFIBRATE COMPARED TO CERIVASTATIN ALONE, FENOFIBRATE ALONE, AND PLACEBO IN A POPULATION OF TYPE 2 DIABETIC MEN AND WOMEN
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

A DOUBLE-BLIND, RANDOMIZED STUDY OF THE SAFETY AND EFFICACY OF A COMBINATION OF INSULIN AND 45 MG OF ACTOS (PIOGLITAZONE) COMPARED TO A COMBINATION OF INSULIN AND 30 MG OF ACTOS (PIOGLITAZONE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 (NON-INSULIN DEPENDENT) DIABETES MELLITUS)
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

DIABETES PREVENTION TRIAL OF TYPE I DIABETES
(PRINCIPAL INVESTIGATOR, 1999 - 2001)

A DOUBLE-BLIND, RANDOMIZED STUDY OF THE SAFETY AND EFFICACY OF A COMBINATION OF SULFONYLUREA AND 45 MG OF PIOGLITAZONE COMPARED TO A COMBINATION OF SULFONYLUREA AND 30 MG OF PIOGLITAZONE IN THE TREATMENT OF PATIENTS WITH TYPE 2 (NON-INSULIN DEPENDENT) DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 1999 - 2001)

A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL, GLYBURIDE-CONTROLLED CARDIAC SAFETY STUDY OF ORAL GL262570 SODIUM TABLETS (7.5 MG) OR MICRONIZED GLYBURIDE 6 - 12 MG ADMINISTERED FOR 24 MONTHS TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR, 1999 - 2001)

A MULTICENTER, OPEN LABEL, FIXED DOSE EXTENSION TO STUDY B356-E-00 TO PROSPECTIVELY EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF CDJN608 MONOTHERAPY IN SUBJECTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS INADEQUATELY CONTROLLED WITH DIET ALONE
(PRINCIPAL INVESTIGATOR, 1998 - 2000)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF METFORMIN/GLYBURIDE TABLETS AS FIRST LINE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ("ASSET" TRIAL)
(PRINCIPAL INVESTIGATOR, 2000 - 2001)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED, PARALLEL, STUDY TO EVALUATE THE GLUCOSE-LOWERING EFFICACY, LIPID-ALTERING EFFICACY, SAFETY AND TOLERABILITY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES
(PRINCIPAL INVESTIGATOR, 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED, PARALLEL, STUDY TO EVALUATE THE GLUCOSE-LOWERING EFFICACY, LIPID-ALTERING EFFICACY, SAFETY AND TOLERABILITY OF L-410198 IN PATIENTS WITH TYPE 2 DIABETES - ECHOCARDIOGRAPHIC SUBSTUDY
(PRINCIPAL INVESTIGATOR, 2000)

A DOUBLE-BLIND, MULTICENTER, RANDOMIZED, PARALLEL GROUP, PHASE III STUDY COMPARING THE TOLERABILITY AND SAFETY OF 2000 MG AND 2500 MG OF METFORMIN XT QD TO THE SAME DOSE OF GLUCOPHAGE BID IN PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM)
(PRINCIPAL INVESTIGATOR, 2000)

A 52 WEEK, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY OF ORLISTAT TREATMENT IN OBESE PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH INSULIN
(PRINCIPAL INVESTIGATOR, 1998 - 2000)

A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED TRIAL TO DETERMINE THE EFFECTS OF A RANGE OF DOSES OF METFORMIN NOVEL ORAL DOSE FORM (BIPHASIC TABLET) ADMINISTERED EITHER ONCE OR TWICE A DAY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE
(PRINCIPAL INVESTIGATOR, 1998 - 2000)

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY, TOLERABILITY, AND SAFETY OF SDZ DJN 608 MONOTHERAPY, TROGLITAZONE MONOTHERAPY AND A COMBINATION OF SDZ DJN 608 AND TROGLITAZONE TO PLACEBO IN SUBJECTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS INADEQUATELY CONTROLLED ON DIET ALONE
(PRINCIPAL INVESTIGATOR, 1998 - 2000)

AN OPEN-LABEL, LONG-TERM EXTENSION STUDY OF PIOGLITAZONE IN TYPE 2 DIABETES MELLITUS PATIENTS (NON-INSULIN DEPENDENT DIABETES MELLITUS, NIDDM)
(PRINCIPAL INVESTIGATOR, 1998 - 1999)

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF THE SAFETY AND EFFICACY OF A COMBINATION OF INSULIN AND TWO DOSES OF PIOGLITAZONE (15 OR 30 MG) IN THE TREATMENT OF PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM)
(PRINCIPAL INVESTIGATOR, 1997 - 1998)

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF THE SAFETY AND EFFICACY OF A COMBINATION OF METFORMIN AND 30 MG PIOGLITAZONE IN THE TREATMENT OF PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM)
(PRINCIPAL INVESTIGATOR, 1997 - 1998)

ATORVASTATIN/DIABETES EXTENSION STUDY
(PRINCIPAL INVESTIGATOR, 1995-1997)

COMPARATIVE OUTCOMES STUDY. METFORMIN INTERVENTION VS CONVENTIONAL APPROACH (COSMIC)
(PRINCIPAL INVESTIGATOR, 1995 - 1996)

PRECOSE RESOLUTION OF OPTIMAL TITRATION TO ENHANCE CURRENT TREATMENT ("P.R.O.T.E.C.T.")
(PRINCIPAL INVESTIGATOR, 1996 - 1997)

CLINICAL TRIAL OF INFUSAID INPLANTABLE INSULIN PUMPS IN PATIENTS WITH TYPE I DIABETES MELLITUS
(PRINCIPAL INVESTIGATOR 1992-1995)

DOUBLE BLIND STUDY OF A ATORVASTATIN COMPARED TO SIMVASTATIN IN LOWERING CHOLESTEROL IN PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS PATIENTS WITH DYSLIPIDEMIA
(PRINCIPAL INVESTIGATOR 1994-1995)

GLYBURIDE KINETIC STUDY / CASE CONTROLLED TRIAL TO DETERMINE THE KINETICS OF GLYBURIDE IN PATIENTS WITH DIABETES AND RENAL FAILURE COMPARED WITH PATIENTS WITH DIABETES AND RELATIVELY NORMAL RENAL FUNCTION
(CO-INVESTIGATOR 1991-1993)

L-MARC HOME PAGE